Notice NOT-MH-18-076 from the NIH Guide for Grants and Contracts

Notice NOT-EY-19-004 from the NIH Guide for Grants and Contracts

Notice NOT-EY-19-005 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-069 from the NIH Guide for Grants and Contracts. REISSUE of PAR-18-733 The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The overall goal of the Gabriella Miller Kids First Pediatric Data Resource is to help researchers understand the underlying mechanisms of these conditions, leading to more refined diagnostic capabilities and ultimately more targeted therapies, as well as to develop an integrated pediatric research data resource by obtaining and aggregating genome sequence and phenotype data for as many relevant structural birth defects and pediatric cancer cohorts as possible and to advance research in this area through the broad sharing of these data with the research community. This FOA is intended to promote meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed.

Notice NOT-OD-19-034 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-070 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing research on current topics in Alzheimer's disease and its related dementias. Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this FOA.

Funding Opportunity PAR-19-071 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing new tests, animal models, techniques, etc. to advance research on Alzheimer's disease and its related dementias and which need additional preliminary data with broader dissemination to establish them for more general use in this research field. The priority topics will be announced through a series of Notices published subsequent to this FOA.

Negotiable: Paramount Recruitment: Lead Software Developer (Front-End) A new opportunity is now available for a talented Lead Developer to join a fantastic Biotech company, working in the field of Genomics and Bioinformatics! Using your background in UI Development and management, the Cambridge, England

Negotiable: Paramount Recruitment: Developer Team Lead (UI) - Cambridge A new opportunity is now available for a talented Lead Developer to join a fantastic Biotech company, working in the field of Genomics and Bioinformatics! Using your background in UI Development and management, the Cambridge, England

Negotiable: Paramount Recruitment: Senior Software Engineer - Python (Bioinformatics) A new opportunity is now available for a Senior Python Software Developer to join a unique start-up company based in Cambridge, working in the field of Genomics and Bioinformatics. Cambridge, England

Funding Opportunity RFA-AA-19-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement applications for research that advances promising compounds thorough the drug development pipeline for the treatment of Alcohol Use Disorder (AUD). NIAAA is seeking applications for medications development research projects from both for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, small businesses not eligible for the SBIR/STTR program and single entities able to demonstrate significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. The aim of this FOA is to move candidate compounds through Investigational New Drug (IND) requirements, Phase 1 human safety, tolerability, and dosing studies, and Phase 2 human laboratory and proof-of-concept trials. Within these phases of drug development, each proposed project should have a defined entry and exit point. Finally, this FOA will not support animal studies to prove efficacy of the candidate compound unless required by the Food and Drug Administration or peer review. Applicants are strongly encouraged to contact the NIAAA Division of Medications Development Staff prior to submitting to this FOA.

Notice NOT-DA-19-010 from the NIH Guide for Grants and Contracts

Notice NOT-DA-19-009 from the NIH Guide for Grants and Contracts

Notice NOT-MH-18-073 from the NIH Guide for Grants and Contracts

Notice NOT-DC-19-002 from the NIH Guide for Grants and Contracts

Negotiable: Paramount Recruitment: Scientist Machine Learning - Bioinformatics Senior level, permanent, Immunology! A fantastic new opportunity has become available for a Bioinformatics Scientist specialising in Machine Learning to join a biopharma company in Baden-Wuerttemberg. Baden-Württemberg, Germany

Notice NOT-CA-19-011 from the NIH Guide for Grants and Contracts

Notice NOT-AG-18-045 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: Bioinformatics Software Engineer Location: Cambridge, Cambridgeshire, England

Funding Opportunity RFA-DE-19-008 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.